Akiyoshi Kasuga

Employment

Employment history is unavailable.

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (35)

• Current Status of Targeted Therapy for Biliary Tract Cancer in the Era of Precision Medicine
  Cancers 2024 DOI: 10.3390/cancers16050879
  +Save
• Splenic Hilar Involvement and Sinistral Portal Hypertension in Unresectable Pancreatic Tail Cancer
  Cancers 2023 DOI: 10.3390/cancers15245862
  +Save
• Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer
  Cancers 2023 DOI: 10.3390/cancers15020358
  +Save
• Outcomes of Intraductal Placement of Covered Metal Stents for Unresectable Distal Malignant Biliary Obstruction
  Journal of Clinical Medicine 2023 DOI: 10.3390/jcm12052001
  +Save
• Safety and Effectiveness of Chemotherapy in Elderly Biliary Tract Cancer Patients
  Current Oncology 2023 DOI: 10.3390/curroncol30080524
  +Save
• Pixel-Level Clustering of Hematoxylin–Eosin-Stained Sections of Mouse and Human Biliary Tract Cancer
  Biomedicines 2022 DOI: 10.3390/biomedicines10123133
  +Save
• Endoscopic Transluminal Stent Placement for Malignant Afferent Loop Obstruction
  Journal of Clinical Medicine 2022 DOI: 10.3390/jcm11216357
  +Save
• Lung Adenocarcinoma Mouse Models Based on Orthotopic Transplantation of Syngeneic Tumor-Initiating Cells Expressing EpCAM, SCA-1, and Ly6d
  Cancers 2020 DOI: 10.3390/cancers12123805
  +Save
• Post-progression survival following second-line chemotherapy in patients with advanced pancreatic cancer previously treated with gemcitabine: a meta-analysis.
  Investigational new drugs 2018 DOI: 10.1007/s10637-018-0589-6
  +Save
• The Modified Glasgow Prognostic Score in Patients with Gemcitabine-refractory Biliary Tract Cancer.
  Anticancer research 2018 DOI: 10.21873/anticanres.12412
  +Save